Aptose Biosciences Inc's Comment on Sales, Marketing and Customers
Aptose is developing a triple drug therapy for newly diagnosed acute myeloid leukemia (AML) patients, including those with mutations such as TP53-mutated/complex karyotype, FLT3-wildtype, FLT3-ITD, and NPM1 mutations. The treatment combines tuspetinib (TUS) with venetoclax (VEN) and azacitidine (AZA). Patients have been treated at TUS dose levels of 40 mg, 80 mg, and 120 mg, achieving complete remissions and measurable residual disease (MRD) negativity. The therapy is mutation-agnostic and has been well-tolerated with no significant safety concerns reported. The Phase 1/2 TUSCANY trial is ongoing, with regulatory approval to escalate doses based on favorable safety and efficacy data.
The European Hematology Association (EHA) 2024 Hybrid Congress witnessed a groundbreaking revelation in the field of hematological research, as Aptose Biosciences presented remarkable clinical and preclinical findings for their drug Tuspetinib (TUS). These findings hold significant implications for the company s future endeavors and the advancement of treatment options for patients.Aptose Biosciences, a renowned biopharmaceutical company, unveiled their state-of-the-art drug, Tuspetinib (TUS), during the European Hematology Association (EHA) 2024 Hybrid Congress. This annual event provides a unique platform for leading experts and researchers to share their latest findings, advancements, and innovative thera...
Aptose Biosciences Inc’s Comment on Sales, Marketing and Customers
Aptose is developing a triple drug therapy for newly diagnosed acute myeloid leukemia (AML) patients, including those with mutations such as TP53-mutated/complex karyotype, FLT3-wildtype, FLT3-ITD, and NPM1 mutations. The treatment combines tuspetinib (TUS) with venetoclax (VEN) and azacitidine (AZA). Patients have been treated at TUS dose levels of 40 mg, 80 mg, and 120 mg, achieving complete remissions and measurable residual disease (MRD) negativity. The therapy is mutation-agnostic and has been well-tolerated with no significant safety concerns reported. The Phase 1/2 TUSCANY trial is ongoing, with regulatory approval to escalate doses based on favorable safety and efficacy data.
Sources:
Aptose Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Aptose Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Aptose Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
